Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

FcgammaRIIa and FcgammaRIIIa genetic polymorphisms in a group of pediatric immune thrombocytopenic purpura in Egypt.

Authors: Eyada, TK  Farawela, HM  Khorshied, MM  Shaheen, IA  Selim, NM  Khalifa, IA 
Citation: Eyada TK, etal., Blood Coagul Fibrinolysis. 2012 Jan;23(1):64-8. doi: 10.1097/MBC.0b013e32834ddf2f.
Pubmed: (View Article at PubMed) PMID:22123287
DOI: Full-text: DOI:10.1097/MBC.0b013e32834ddf2f

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder caused by the production of antiplatelet antibodies. The current case-control study aimed at detecting the frequency of FcgammaRIIa-131H/R and FcgammaRIIIa-158F/V genes polymorphism in Egyptian children with ITP as genetic markers for ITP risk, and to clear out their possible role in choosing the treatment protocols of ITP. To achieve this aim, FcgammaRIIa genotyping was tested by PCR-restriction fragment length polymorphism (RFLP) technique, whereas FcgammaRIIIa genotyping was tested by nested PCR followed RFLP analysis. The current case-control study was conducted on 92 children with ITP; 12 acute and 80 chronic cases and 90 controls. The V allele and FcgammaRIIIa FV heterotype were significantly higher in ITP patients and conferred increased ITP risk [odds ratio (OR) = 1.96 and 2.55, respectively]. The frequency of FcgammaRIIa H allele was significantly higher among chronic ITP patients. In conclusion, FcgammaRIIIa gene polymorphism may contribute to susceptibility to ITP. Moreover, analysis of the FcgammaR polymorphisms in ITP patients could influence the effectiveness of medications and selection of the line of treatment.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11040989
Created: 2016-03-18
Species: All species
Last Modified: 2016-03-18
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.